These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 16185301)

  • 21. [The cardiovascular effects of serotonin receptor agonists and antagonists (I)].
    Villalón CM; Terrón JA; Hong E; Saxena PR
    Arch Inst Cardiol Mex; 1993; 63(5):441-7. PubMed ID: 8291931
    [No Abstract]   [Full Text] [Related]  

  • 22. 5-HT activates vagal afferent cell bodies in vivo: role of 5-HT2 and 5-HT3 receptors.
    Lacolley P; Owen JR; Sandock K; Lewis TH; Bates JN; Robertson TP; Lewis SJ
    Neuroscience; 2006 Nov; 143(1):273-87. PubMed ID: 17029799
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 5-HT4 receptor antagonism potentiates inhibition of intestinal allodynia by 5-HT3 receptor antagonism in conscious rats.
    Smith MI; Banner SE; Sanger GJ
    Neurosci Lett; 1999 Aug; 271(1):61-4. PubMed ID: 10471214
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of serotonin in irritable bowel syndrome: implications for management.
    Garvin B; Wiley JW
    Curr Gastroenterol Rep; 2008 Aug; 10(4):363-8. PubMed ID: 18627647
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Problems of drug selectivity and dose--pharmacology.
    Ramage A
    J Physiol; 2005 Dec; 569(Pt 2):711; author reply 712. PubMed ID: 16322062
    [No Abstract]   [Full Text] [Related]  

  • 26. Effects of the novel 5-HT3 agonist MKC-733 on the rat, mouse and guinea pig digestive tract.
    Chetty N; Irving HR; Coupar IM
    Pharmacology; 2008; 81(2):104-9. PubMed ID: 17952012
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serotonin decreases generation of dopaminergic neurons from mesencephalic precursors via serotonin type 7 and type 4 receptors.
    Parga J; Rodriguez-Pallares J; Muñoz A; Guerra MJ; Labandeira-Garcia JL
    Dev Neurobiol; 2007 Jan; 67(1):10-22. PubMed ID: 17443768
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics and in vitro effects of tegaserod, a serotonin 5-hydroxytryptamine 4 (5-HT4) receptor agonist with prokinetic activity in horses.
    Delco ML; Nieto JE; Craigmill AL; Stanley SD; Snyder JR
    Vet Ther; 2007; 8(1):77-87. PubMed ID: 17447227
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serotonin 5-HT3 and 5-HT4 ligands: an update of medicinal chemistry research in the last few years.
    Modica MN; Pittalà V; Romeo G; Salerno L; Siracusa MA
    Curr Med Chem; 2010; 17(4):334-62. PubMed ID: 20015043
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serotonin: a review.
    Mohammad-Zadeh LF; Moses L; Gwaltney-Brant SM
    J Vet Pharmacol Ther; 2008 Jun; 31(3):187-99. PubMed ID: 18471139
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Luminal hypotonicity increases duodenal mucosal permeability by a mechanism involving 5-hydroxytryptamine.
    Nylander O; Pihl L
    Acta Physiol (Oxf); 2006 Jan; 186(1):45-58. PubMed ID: 16497179
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Azaadamantane benzamide 5-HT4 agonists: gastrointestinal prokinetic SC-54750.
    Becker DP; Flynn DL; Shone RL; Gullikson G
    Bioorg Med Chem Lett; 2004 Nov; 14(22):5509-12. PubMed ID: 15482914
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Regulatory molecules for the 5-HT3 receptor ion channel gating system.
    Yoshida S; Watanabe T; Sato Y
    Bioorg Med Chem; 2007 May; 15(10):3515-23. PubMed ID: 17391967
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Wood creosote prevents CRF-induced motility via 5-HT3 receptors in proximal and 5-HT4 receptors in distal colon in rats.
    Ataka K; Kuge T; Fujino K; Takahashi T; Fujimiya M
    Auton Neurosci; 2007 May; 133(2):136-45. PubMed ID: 17182287
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Endogenous 5-hydroxytryptamine modulates the release of tachykinins and calcitonin gene-related peptide from the rat spinal cord via 5-HT3 receptors.
    Saria A; Javorsky F; Humpel C; Gamse R
    Ann N Y Acad Sci; 1991; 632():464-5. PubMed ID: 1719904
    [No Abstract]   [Full Text] [Related]  

  • 36. 5-HT4 receptor ligands: applications and new prospects.
    Langlois M; Fischmeister R
    J Med Chem; 2003 Jan; 46(3):319-44. PubMed ID: 12540230
    [No Abstract]   [Full Text] [Related]  

  • 37. Serotonergic signalling in the stomach and duodenum of patients with gastroparesis.
    van Lelyveld N; Ter Linde J; Schipper M; Samsom M
    Neurogastroenterol Motil; 2008 May; 20(5):448-55. PubMed ID: 18208480
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 5-hydroxytryptamine and the gastrointestinal migrating motor complex.
    Plaza MA
    Curr Opin Investig Drugs; 2001 Apr; 2(4):539-44. PubMed ID: 11566014
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular cloning and pharmacological characterization of serotonin 5-HT(3A) receptor subtype in dog.
    Jensen TN; Nielsen J; Frederiksen K; Ebert B
    Eur J Pharmacol; 2006 May; 538(1-3):23-31. PubMed ID: 16647053
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Higher-end serotonin receptors: 5-HT(5), 5-HT(6), and 5-HT(7).
    Glennon RA
    J Med Chem; 2003 Jul; 46(14):2795-812. PubMed ID: 12825922
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.